The D3 dopamine receptor in cellular and organismal function

被引:95
|
作者
Shafer, RA [1 ]
Levant, B [1 ]
机构
[1] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, Kansas City, KS 66160 USA
关键词
limbic system; signal transduction; autoreceptor; receptor binding; behavior; locomotor activity; reward; development schizophrenia; Parkinson's disease; cocaine; antipsychotic;
D O I
10.1007/s002130050479
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The D-3 dopamine receptor is a member of the family of D-2-like dopamine receptors. Since the cloning and identification of the D-3 receptor in 1990, considerable progress has been made towards understanding the function of this novel site. Although some avenues of investigation have yielded more definitive results than others, studies to date indicate the D-3 receptor is localized preferentially in limbic brain areas and affects locomotion and perhaps reinforcement and reward. A subpopulation of the receptors appear to be autoreceptors which modulate dopamine synthesis, release, and neuronal activity. These observations have led to the hypothesis that the D-3 receptor may be an appropriate target in the treatment of neuropsychiatric disorders such as schizophrenia and drug addiction. The role of D-3 sites in disease, however, remains to be established. Genetic association of D-3 receptor polymorphisms with neuropsychiatric disorders have been proposed. Alterations in expression of Dg sites may occur in some diseases. Although the study of this receptor is clearly in the early stages, these findings lay the foundation for future investigation. In this review, dopamine D-3 receptor brain localization, cellular signaling mechanisms, and associated behavior will be discussed. The potential role of the D-3 site in neuropsychiatric disorders and as a therapeutic target is also addressed.
引用
收藏
页码:1 / 16
页数:16
相关论文
共 50 条
  • [31] Neuroprotective effects of D3 dopamine receptor agonists
    Carvey, PM
    McGuire, SO
    Ling, ZD
    PARKINSONISM & RELATED DISORDERS, 2001, 7 (03) : 213 - 223
  • [32] SH3 ligands in the dopamine D3 receptor
    Oldenhof, J
    Ray, A
    Vickery, R
    Van Tol, HHM
    CELLULAR SIGNALLING, 2001, 13 (06) : 411 - 416
  • [33] Dopamine D3 receptor mRNA and renal response to D3 receptor activation in spontaneously hypertensive rats
    Luippold, G
    Piesch, C
    Osswald, H
    Mühlbauer, B
    HYPERTENSION RESEARCH, 2003, 26 (10) : 855 - 861
  • [34] Discovery of a Novel Dopamine D3 Receptor Inhibitor
    Deng Xin-Xian
    Shen Qing
    Xu Li-Li
    Xiong Zi-Jun
    Zhao Wei-Li
    Zhen Xue-Chu
    Fu Wei
    CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2011, 32 (08): : 1779 - 1784
  • [35] Role of the D3 dopamine receptor in nicotine sensitization
    Smith, Laura N.
    Bachus, Susan E.
    McDonald, Craig G.
    Smith, Robert F.
    BEHAVIOURAL BRAIN RESEARCH, 2015, 289 : 92 - 104
  • [36] Dopamine D3 receptor antagonists as therapeutic agents
    Joyce, JN
    Milian, MJ
    DRUG DISCOVERY TODAY, 2005, 10 (13) : 917 - 925
  • [37] Susceptibility to schizophrenia and the dopamine D3 receptor gene
    Wilcox, JA
    BIOLOGICAL PSYCHIATRY, 1999, 45 (08) : 27S - 27S
  • [38] Dopamine D3 receptor agonists as pharmacological tools
    Kassel, S.
    Schwed, J. S.
    Stark, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (09) : 1480 - 1499
  • [39] Dopamine D3 receptor variant and tardive dyskinesia
    Rietschel, M
    Krauss, H
    Müller, DJ
    Schulze, TG
    Knapp, M
    Marwinski, K
    Maroldt, AO
    Paus, S
    Grünhage, F
    Propping, P
    Maier, W
    Held, T
    Nothen, MM
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2000, 250 (01) : 31 - 35
  • [40] Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands
    Laszlovszky, I
    Acs, T
    Kiss, B
    Domány, G
    PHARMAZIE, 2001, 56 (04): : 287 - 289